The Europe Cough Syrup Market would witness market growth of 5.4% CAGR during the forecast period (2020-2026). As per WHO (World Health Organization), around 4.3 million deaths caused by indoor air pollution in a year.
There are various diseases and deaths, which is caused due to the prolonged exposure to poor indoor air quality majorly causes in women and children, specifically in low-income families. These factors can result in lung cancer, COPD, and, in children, it can also cause pneumonia and asthma. A considerable population has some kind of respiratory issue owing to air pollution that will propel the growth of the cough syrup market as it is an important medication utilized for the treatment of some diseases.
The rising prevalence of respiratory problems coupled with increasing air pollution is among the main factors driving the growth of the market in the coming years. Moreover, the growing geriatric population with an active pharmaceutical industry is supporting the growth of the market as older people are prone to respiratory issues. In addition, the ever-growing enhancements in products are projected to provide new growth prospects for the cough syrup market.
The increasing cases of respiratory issues are providing lucrative opportunities for the cough syrup market. Moreover, the rising population of old age people along with increasing air pollution are driving the growth of the market. However, the misuse of cough syrup coupled with the strict rules & regulations by the government will restrict the market growth. On the other hand, the high market potential of the developing regions will garner more growth opportunities for the cough syrup market growth.
The Germany market dominated the Europe Pediatric Market by Country in 2019, growing at a CAGR of 5.7 % during the forecast period. The UK market is exhibiting a CAGR of 5.5% during (2020 - 2026). Additionally, The France market is poised to grow at a CAGR of 8.3% during (2020 - 2026).
The Retail Pharmacy market dominated the Spain Cough Syrup Market by Distribution Channel in 2019, thereby, achieving a market value of $85.9 million by 2026. The Hospital Pharmacy market is expected to witness a CAGR of 5% during (2020 - 2026).
Based on Product, the market is segmented into Cough Suppressants, Combination Medications and Expectorants. Based on Age Group, the market is segmented into Adult and Pediatric. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: Cough Syrup Market in Europe is expected to register a CAGR of 5.4% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Novartis AG, Merck Group, Johnson and Johnson, GlaxoSmithKline PLC (GSK), The Procter and Gamble Company, Reckitt Benckiser Group PLC, Abbott Laboratories, Sanofi S.A., and Acella Pharmaceuticals, LLC (Alora Pharmaceuticals, LLC).
By Product
By Age Group
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
